512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies. - Aggarwal, R.; Umetsu, S.; Dhawan, M.; Grabowsky, J.; Carnevale, J.; Howell, M.; Wilch, L.; Chapman, J.; Alvarez, E.; Calabrese, S.; Smith, S.; Shah, N.; et al. (Annals of Oncology, 2021)